Varenicline was revealed at Pfizer through the research intended at changing the composition of cytisine, [9] a European smoking cessation aid and also a half-done α4β2-nicotinic antagonist. [10][11]

Varenicline acknowledged a “priority review” by the U.S. Food and Drug Administration in February 2006, curbing the usual 10-month evaluation period to 6 months because of its established helpfulness in clinical trials and supposed short of protection issues.[12]

 The agency’s authorization of the drug came on May 11, 2006.[2].

Beginning August 1, 2006, varenicline has been accessible for sale in the United States, and on

September 29, 2006, it was accepted for sale in the European Union.